A subcutaneous (SC) injection version of Roche’s big-selling multiple sclerosis therapy Ocrevus has matched the current intravenous form in a clinical trial and, according to the company ...

The exploratory outcomes of the trial revealed that Ocrevus Zunovo matched the intravenous version in suppressing relapse ...

Ocrevus generated 1.04 billion Swiss francs – more than 90% of that was from use in the US. The treatment for relapsing remitting and primary progressive MS is taken as an intravenous infusion ...

An IV infusion is an injection into a vein that ... talk with your doctor before receiving Tysabri: Ocrevus is also approved to treat primary progressive MS, while Tysabri is not approved ...

It’s administered as a 4-hour intravenous infusion after the starting ... “FDA Approves Kesimpta® (ofatumumab), Similar to Ocrevus®, for Relapsing MS,” “Non-approved treatments used ...

Ocrevus is a medicine commonly used to treat primary progressive MS, but it can take up to four hours to receive intravenously. A new version called “Ocrevus Zunovo” was recently approved by ...

You get this drug as an IV infusion at your doctor’s office ... FDA Approves Kesimpta® (ofatumumab), Similar to Ocrevus®, for Relapsing MS,” “Guide to Prescription Financial Assistance.” ...

Briumvi is going up against a giant in multiple sclerosis treatment. Roche sells its drug, Ocrevus, as an intravenous ...

TG Therapeutics' Q3 earnings missed EPS expectations despite Briumvi's revenue growth. See why TGTX stock is a Buy.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results ...

Additionally, Briumvi is projected to become a leading product in the intravenous anti-CD20 market within five years, with potential cannibalization from Ocrevus’ subcutaneous formulation. The survey ...

With OCREVUS ZUNOVO, multiple sclerosis patients can now receive their treatment as a 10 minute subcutaneous injection given twice a year, compared to a multi-hour treatment for the intravenous ...